2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
2
Status
Not yet recruiting
1
Completed
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Plasma cell
2
Conditions
Immunoglobulin Light-chain Amyloidosis
3
Multiple Myeloma
2
Amyloidosis
2
Paraproteinemias
1
Monoclonal Gammopathy of Undetermined Significance
1
Amyloid Neuropathies, Familial
1
Interventions
Dexamethasone
809
Bortezomib
449
Lenalidomide
430
Cyclophosphamide
336
Melphalan
251
Calcium Dobesilate
237
daratumumab
218
pomalidomide
202
carfilzomib
181
fludarabine phosphate
131
Thalidomide
121
fludarabine
118
Peripheral Blood Stem Cell Transplantation
117
Filgrastim
111
ixazomib
85
Mycophenolic Acid
85
Granulocyte Colony-Stimulating Factor
84
Busulfan
83
Whole-Body Irradiation
80
Tacrolimus
75
dexamethasone acetate
74
Cyclosporine
67
isatuximab
64
Prednisone
64
dexamethasone 21-phosphate
63
elotuzumab
60
auricularum
57
belantamab mafodotin
55
Antilymphocyte Serum
55
Etoposide
52
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Multiple Myeloma
×
4-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene
×
Clear all
NCT07624760
2026-06-03
MGUS-PET
University of Zurich
Phase NA
Not yet recruiting
50 enrolled
NCT03779815
2019-04-18
PET
Ulsan University Hospital
Phase NA
Completed
14 enrolled